Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2139-2148

  Zhang, Lei ^a   Xu, Xuan ^a   Yang, Ruhao ^a   Chen, Jingwen ^a   Wang, Shixuan ^c   Yang, Junqin ^a   Xiang, Xudong ^a   He, Zhibiao ^a   Zhao, Yu ^b   Dong, Zheng ^a,c   Zhang, Dongshan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Harbin the First Hospital   (China)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Paclitaxel; STAT3; Tubulin; Tubulointerstitial fibrosis; UUO

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CYTOKINE; FIBRONECTIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; PACLITAXEL; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUBULIN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; STAT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FIBROBLAST; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KIDNEY DISEASE; KIDNEY FIBROSIS; LOW DRUG DOSE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; URETER OBSTRUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; FIBROSIS; KIDNEY; MALE; METABOLISM; NEPHRITIS, INTERSTITIAL; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; FIBROSIS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; NEPHRITIS, INTERSTITIAL; PACLITAXEL; STAT3 TRANSCRIPTION FACTOR; TUBULIN;

EID: 84929207986     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S81390     Document Type: Article

References (32)

1. Zhang D, Yang, R, Wang S, Dong Z. Paclitaxel: new uses for an old drug. Drug Des Devel Ther. 2014;20(8):279-284.
2. Zhang D, Sun L, Xian W, et al. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-β/Smad activity. Lab Invest. 2010;90(3):436-447.
3. Karbalay-Doust S, Noorafshan A, Pourshahid SM. Taxol and taurine protect the renal tissue of rats after unilateral ureteral obstruction: a stereological survey. Korean J Urol. 2012;53(5):360-367.
4. Sun L, Zhang D, Liu F, et al. Low-dose paclitaxel ameliorates fibrosis in the remnant kidney model by down-regulating miR-192. J Pathol. 2011;225(3):364-377.
5. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
6. Neilson EG. Mechanisms of disease: fibroblasts-a new look at an old problem. Nat Clin Pract Nephrol. 2006;2(2):101-108.
7. Horvath CM. STAT proteins and transcriptional responses to extracellular signals. Trends Biochem Sci. 2000;25(10):496-502.
8. Fuller GM, Zhang Z. Transcriptional control mechanism of fibrinogen gene expression. Ann N Y Acad Sci. 2001;936:469-479.
9. Ogata H, Chinen T, Yoshida T, et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene. 2006;25(17):2520-2530.
10. Kuratsune M, Masaki T, Hirai T, et al. Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction. Nephrology (Carlton). 2007;12(6):565-571.
11. Pang M, Ma L, Gong R, et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 2010;78(3):257-268.
12. Walker SR, Chaudhury M, Nelson EA, Frank DA. Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol Pharmacol. 2010;78(5):903-908.
13. Zhang D, Li Y, Liu Y, et al. Paclitaxel ameliorates lipopolysaccharide-induced kidney injury by binding myeloid differentiation protein-2 to block toll-like receptor 4-mediated nuclear factor-κB activation and cytokine production. J Pharmacol Exp Ther. 2013;345(1):69-75.
14. Zhang D, Liu Y, Wei Q, et al. Tubular p53 regulates multiple genes to mediate AKI. J Am Soc Nephrol. 2014;25(10):2278-2289.
15. Grande MT, Lopez-Novoa JM. Fibroblast activation and myofibroblast generation in obstructive nephropathy. Nat Rev Nephrol. 2009;5(6):319-328.
16. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007;104(18):7391-7396.
17. Yamamoto T, Matsuda T, Muraguchi A, et al. Cross-talk between IL-6 and TGF-beta signaling in hepatoma cells. FEBS Lett. 2001;492(3):247-253.
18. Vij N, Sharma A, Thakkar M, et al. PDGF-driven proliferation, migration, and IL8 chemokine secretion in human corneal fibroblasts involve JAK2 STAT3 signaling pathway. Mol Vis. 2008;14(23):1020-1027.
19. Kretzschmar AK, Dinger MC, Henze C, et al. Analysis of Stat3 (signal transducer and activator of transcription 3) dimerization by fluorescence resonance energy transfer in living cells. Biochem J. 2004;377:289-297.
20. Lim CP, Phan TT, Lim IJ, et al. Cytokine profiling and Stat3 phosphorylation in epithelial-mesenchymal interactions between keloid keratinocytes and fibroblasts. J Invest Dermatol. 2009;129(4):851-861.
21. Lane A, Johnson DW, Pat B, et al. Interacting roles of myofibroblasts, apoptosis and fibrogenic growth factors in the pathogenesis of renal tubulointerstitial fibrosis. Growth Factors. 2002;20 (3):109-119.
22. Vesey DA, Cheung CW, Cuttle L, et al. Interleukin-1beta induces human proximal tubule cell injury, alpha-smooth muscle actin expression and fibronectin production. Kidney Int. 2002;62(1):31-40.
23. Arakawa T, Masaki T, Hirai T, et al. Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis. Nephrol Dial Transplant. 2008;23(11):3418-3426.
24. Berthier CC, Zhang H, Schin M, et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes. 2009;58(2):469-477.
25. Herrmann JE, Imura T, Song B, et al. STAT3 is a critical regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci. 2008;28(28):7231-7243.
26. Milanović D, Braun F, Weber W, et al. The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts. BMC Cancer. 2012;12:242.
27. Abubaker K, Luwor RB, Escalona R, et al. Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden. Front Oncol. 2014;4:75.
28. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5):1899-1911.
29. Vidt DG. Inflammation in renal disease. Am J Cardiol. 2006;97(2 A):20A-27A.
30. Zhang C, Li Y, Wu Y, et al. Interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast proliferation during muscle regeneration. J Biol Chem. 2013;288(7):1489-1499.
31. Zeisberg M, Maeshima Y, Mosterman B, et al. Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol. 2002;160(6):2001-2008.
32. Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens. 2003;12(1):25-29.